Rituximab adjunctive therapy for Burkitt's lymphoma

An open-label, randomised, phase 2 study of rituximab as adjunctive therapy in the treatment of Burkitt’s lymphoma at QECH, Blantyre, Malawi

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN90296187

Enrollment

180

Registered

2016-06-17

Start date

2016-06-20

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burkitt's lymphoma Cancer

Interventions

This study tests whether the addition of a single dose of rituximab to standard anti-lymphoma therapy will improve outcome in newly diagnosed, relapsed and resistant eBL. All patients will receive the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Child <14 yrs of age with proven Burkitt's lymphoma (BL) or relapse or resistant BL 2. After full information, the guardians have given written informed consent, and the child if appropriate will be asked for assent 3. The guardian and patient will be willing and able to complete treatment and follow-up

Exclusion criteria

Exclusion criteria: 1. Patients known to be allergic to trial medications 2. Patients or their guardians who do not consent 3. Pregnant and/or breastfeeding patients

Design outcomes

Primary

Measure	Time frame
Clinical Complete Remission rate at end of chemotherapy	—

Secondary

Measure	Time frame
1. Clinical Complete Remission rate at one year post chemotherapy 2. Severe adverse effects of rituximab	—

Countries

Malawi

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026